Document:

EX-10.25

 Exhibit 10.25 

February 23, 2016 
 Patrick O’Mara 

Dear Patrick: 
 CymaBay Therapeutics (the “Company”)
is pleased to offer you employment as Vice President of Business Development on the following terms: 
 1. Position, Duties and
Responsibilities. Subject to the terms set forth herein, the Company agrees to employ you in the position of as Vice President of Business Development and you hereby accept such employment effective immediately. You will report to the
Company’s Chief Executive Officer (“CEO”) and will perform the duties customarily associated with this position and such other duties as are assigned to you by the CEO. You will devote your full business time and attention to the
business affairs of the Company, except for reasonable vacations and periods of illness or incapacity permitted by the Company’s general employment policies. The employment relationship between you and the Company shall also be governed by the
general employment policies and practices of the Company, including those relating to protection of confidential information and assignment of inventions, except that when the terms of this letter agreement differ from or are in conflict with the
Company’s general employment policies or practices, this letter agreement shall control. 
 2. Compensation and Employee Benefits.

 2.1 Base Salary. Your base salary will be $286,727 on an annualized basis, less payroll deductions and required withholdings,
paid according to the Company’s regular payroll schedule and procedures. Subject to the other terms of this letter agreement, your base salary may be modified by the Company in its sole discretion. Your salary will be effective as of
January 1, 2016. 
 2.2 Discretionary Bonus. You will be eligible to participate in the Company’s annual bonus program
pursuant to the terms of that program and you will be eligible to receive a bonus of up to thirty percent (30%) of your annual base salary. Your actual bonus, if any, will be determined by the Company’s Board of Directors, or the
Compensation subcommittee thereof (the “Board”), in its sole discretion, based upon its evaluation of your performance, the Company’s performance, and any other considerations it deems relevant. You must be employed through the bonus
payment date to be eligible for, and to earn, any such bonus. Any bonus payment will be subject to payroll deductions and required withholdings. 

2.3 Employee Benefits. You will be entitled to all employee benefits, including vacation accrual of twenty (20) days per year and
health and disability benefits for which you are eligible under the terms and conditions of the standard Company benefit plans which may be in effect from time to time and provided by the Company to its senior executive-level employees generally.
Currently, such benefits include twelve paid holidays, as well as paid sick leave of up to ten days per year. Notwithstanding the foregoing, the Company reserves the right to adopt, amend or discontinue any employee benefit plan or policy, including
changes required by applicable law. 

  
 1. 

 2.4 Stock Options. Subject to the approval of the Board pursuant to the Company’s
equity incentive plan you may from time to time be granted stock options of shares of Company common stock at a per share exercise price equal to the per share fair market value of the Company’s common stock on the date of grant as determined
by the Board. Option grants are made at regular Board meetings held approximately once each calendar quarter. Such stock options will vest as determined by the Board, as long as you remain in continuous service with the Company and a portion of the
shares subject to your outstanding options may vest on an accelerated basis pursuant to Sections 7 or 8. Except as provided herein, such stock option will be subject to the provisions of the equity incentive plan of the Company under which the
options are granted and the applicable form of stock option agreement there under (the “Plan Documents”). 
 3. Other
Activities During Employment. 
 3.1 Activities. Except with the prior written consent of the CEO, you will not, during your
employment with the Company, undertake or engage in any other employment, occupation or business enterprise, other than ones in which you are a passive investor. You may engage in civic and not-for-profit activities so long as such activities do not
interfere with the performance of your job duties for the Company. 
 3.2 Investments and Interests. Except as permitted by the first
sentence of Section 3.1 and by Section 3.3, during your employment you agree not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by you to be adverse or antagonistic to the Company,
or its business or prospects, financial or otherwise. 
 3.3 Noncompetition. During the term of your employment by the Company,
except on behalf of the Company, you will not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested
in, be employed by or have any business connection with any other person, corporation, firm, partnership or other entity whatsoever that competes with the Company anywhere in the world, in any line of business engaged in (or planned to be engaged
in) by the Company; provided, however, that anything above to the contrary notwithstanding, you may own, as a passive investor, securities of any entity, so long as your direct holdings in any one such corporation do not in the aggregate
constitute more than one percent (1%) of the voting stock of such corporation. 
 4. Company Policies; Confidential Information and
Inventions Agreement. You acknowledge your obligations under the Company’s Employee Agreement on Confidential Information and Inventions, a copy of which is attached as Exhibit A. You further acknowledge your obligation to abide by the
Company’s rules, policies and procedures. 
 5. Immigration. The Immigration Reform and Control Act of 1986 requires that every
person present proof to the Company of their identity and eligibility and/or authorization to accept employment with the Company. In order to comply with this law you must provide appropriate documentation to prove both your identity and legal
eligibility to be employed at the Company. 

  
 2. 

 6. Your Representations and Warranties. 

6.1 No Breach of Contract. You represent and warrant that the execution and delivery of this letter agreement by you and the
performance of your obligations hereunder will not conflict with or breach any agreement, order or decree to which you are a party or by which you are bound. You warrant that you are subject to no employment agreement or restrictive covenant
preventing full performance of your duties under this letter agreement. 
 6.2 No Conflict of Interest. You warrant that you are not,
to the best of your knowledge and belief, involved in any situation that might create, or appear to create, a conflict of interest with your loyalty to or duties for the Company. 

6.3 Notification of Materials or Documents from Other Employers. You further warrant that you have not brought and will not bring to
the Company or use in the performance of your responsibilities at the Company any materials or documents of a former employer that are not generally available to the public, unless you have obtained express written authorization from the former
employer for their possession and use. 
 6.4 Notification of Other Post-Employment Obligations. You also understand that, as part of
your employment with the Company, you are not to breach any obligation of confidentiality that you have to former employers, and you agree to honor all such obligations to former employers during your employment with the Company. 

7. Termination of Employment. 

7.1 At-Will Employment Relationship. Your employment with the Company shall be at-will. Either you or the Company may terminate the
employment relationship at any time, with or without Cause, and with or without advance notice. 
 7.2 Termination for Cause. 

(a) If the Company terminates your employment at any time for Cause (as defined below), your salary shall cease on the date of
termination and you shall not be entitled to severance pay, COBRA premium payments, pay in lieu of notice or any other such compensation other than payment of accrued salary and vacation and such other benefits as expressly required by applicable
law or the terms of applicable benefit plans. The continued vesting of any stock options held by you shall cease on your employment termination date, and your right to exercise vested options shall be governed by the Plan Documents. 

(b) Definition of Cause. For purposes of this agreement, “Cause” means the occurrence of any one or more of the following:
(i) your conviction of, or plea of no contest, with respect to any felony or any crime involving fraud, dishonesty or moral turpitude; (ii) your participation in a fraud or act of dishonesty that results in material harm to the Company;
(iii) your intentional material violation of any contract or agreement between you and the Company, including but not limited to this letter agreement or your Employee Agreement on Confidential Information and Inventions, or your violation of
any statutory duty that you owe to the Company, but only if you do not correct any such violation within thirty (30) days after written notice thereof has been provided to you (if such notice is reasonably practicable); or (iv) your gross
negligence or willful neglect of your job duties, as determined by the Board in good faith, but only if you do not correct such violation within thirty (30) days after written notice thereof has been provided to you (if such notice is
reasonably practicable). 

  
 3. 

 7.3 Severance Benefits For Termination Without Cause or Resignation for Good Reason. 

(a) If the Company terminates your employment without Cause and other than as a result of your death or disability, or if you resign
your employment for Good Reason (defined below), and provided such termination constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder,
a “Separation from Service”), you will be eligible to receive the severance benefits described in this Section 7.3. 

(b) You will be eligible to receive, subject to payroll deductions and required withholdings and net of any amounts earned by you
pursuant to any employment or consulting arrangements obtained by you following such termination (other than the activities described in the last sentence of Section 3.1), continuation for nine (9) months of the greater of: (i) your
base salary in effect as of such termination date; or (ii) your base salary as set forth in Section 2.1. In addition, you will be eligible to receive your potential annual discretionary bonus amount set forth in Section 2.2,
determined as if all performance targets established by the Board have been satisfied, pro-rated for the number of months elapsed in the year in which your employment terminates, but in no event will you receive a bonus pro-rated for greater than
nine (9) months. You agree to notify the Company promptly of any amount earned by you from other employment or a consulting engagement while you are receiving severance payments under this letter agreement. 

(c) If you timely elect and remain eligible for continued coverage of your group health insurance under COBRA, the Company will pay
your premiums for COBRA coverage for up to nine (9) months following your Separation from Service, provided that such payments shall cease if you obtain full-time employment, or cease to be eligible for COBRA, within such period. You agree to
notify the Company promptly if you obtain full-time employment while the Company is paying your COBRA premiums under this letter agreement. On the 60th day following your Separation from Service,
the Company will make the first payment under this clause equal to the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such 60th day, with the balance of the payments paid thereafter on the schedule described above. If you become eligible for coverage under another employer’s group health plan or otherwise cease to be
eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause will cease. 

(d) You will receive acceleration of vesting of all of your then-outstanding and then-unvested stock option grants as of the date of
termination as to the number of shares that would have vested in their vesting schedules as if you had been in service for an additional nine (9) months as of your Separation from Service. 

(e) Your receipt of any severance benefits under this Section 7.3 is contingent upon your signing and making effective within
sixty (60) days after the termination date, a full, general release of all claims against the Company in a form acceptable to the Company containing the language set forth in the Release Agreement attached as Exhibit B on or after the
termination date. The base salary and bonus severance will be paid in substantially equal installments over the nine (9) month period following your Separation in Service according 

  
 4. 

 
to the Company’s payroll procedures; provided, however, that no payments will be made to you prior to the 60th day following your Separation from Service. On the first payroll pay day
following the 60th day after your Separation from Service, the Company will pay you the cash severance amounts you would have received on or prior to such date in a lump sum in compliance with Code Section 409A and the effectiveness of the
release, with the balance of the cash payments being made as originally scheduled. 
 (f) Definition of Good Reason. For purposes of
this letter agreement, “Good Reason” shall mean any one of the following events that occurs without your consent: (i) the material reduction in your responsibilities, authorities or functions as an employee of the Company (but not
merely a change in reporting relationships); (ii) a material reduction in your level of compensation (including base salary, fringe benefits and target bonus under any corporate-performance based bonus or incentive programs); (iii) a
material change of your place of employment that results in an increase to your round trip commute of more than fifty (50) miles; or (iv) the Company’s material breach of this letter agreement. Notwithstanding the foregoing, you must
provide written notice to the Chief Financial Officer of the Company within thirty (30) days after the date on which such event first occurs, and allow the Company thirty (30) days thereafter (the “Cure Period”) during which the
Company may attempt to rescind or correct the matter giving rise to Good Reason. If the Company does not rescind or correct the conduct giving rise to Good Reason to your reasonable satisfaction by the expiration of the Cure Period, your employment
will then terminate with Good Reason as of such thirtieth day. 
 7.4 Voluntary or Mutual Termination. You may voluntarily terminate
your employment with the Company at any time without Good Reason. If you terminate without Good Reason or if your employment terminates as a result of your death or disability, your salary shall cease on the date of termination and you shall not be
entitled to severance, pay in lieu of notice or any other such compensation other than payment of accrued salary and vacation and such other benefits as expressly required in such event by applicable law or the terms of applicable benefit plans. The
continued vesting of any compensatory equity awards held by you shall cease on the termination date, and your right to exercise vested awards (or be issued shares under such vested awards) shall be governed by the terms of the Company’s
applicable compensatory equity plans and the corresponding award agreements. 
 7.5 Application of Section 409A. If the Company
(or, if applicable, the successor entity thereto) determines that the severance payments and benefits provided for in this letter agreement (the “Agreement Payments”) constitute “deferred compensation” under Section 409A of
the Internal Revenue Code (together, with any state law of similar effect, “Section 409A”) and you are a “specified employee” of the Company or any successor entity thereto, as such term is defined in
Section 409A(a)(2)(B)(i) (a “Specified Employee”), then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Agreement Payments shall be delayed as
follows: on the earliest to occur of (i) the date that is six months and one day after the termination date or (ii) the date of your death (such earliest date, the “Delayed Initial Payment Date”), the Company (or the successor
entity thereto, as applicable) shall (A) pay to you a lump sum amount equal to the sum of the Agreement Payments that you would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the Agreement
Payments had not been delayed pursuant to this Section 7.5 and (B) commence paying the balance of the Agreement Payments in accordance with the applicable payment schedules set forth in this letter agreement.

  
 5. 

 
For the avoidance of doubt, it is intended that (1) each installment of the Agreement Payments provided in this letter agreement is a separate “payment” for purposes of
Section 409A, (2) all Agreement Payments satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under of Treasury Regulation 1.409A-1(b)(4) and 1.409A-1(b)(9)(iii), and (3) the
Agreement Payments consisting of COBRA premiums also satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation 1.409A-1(b)(9)(v). 

8. Change in Control. 

8.1 Definitions. 

(a) “Change in Control” shall mean an Ownership Change Event (as defined below) or a series of related Ownership Change
Events (collectively, a “Transaction”) wherein the stockholders of the Company immediately before the Transaction do not retain direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting
power of the outstanding securities of the Company or, in the case of a Transaction described in Section 8.1(b)(iii), the corporation or other business entity to which the assets of the Company were transferred (the “Transferee”), as
the case may be. For purposes of the preceding sentence, indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities that own
the Company or the Transferee, as the case may be, either directly or through one or more subsidiary corporations or other business entities. 

(b) An “Ownership Change Event” shall be deemed to have occurred if any of the following occurs with respect to the Company:
(i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more than fifty percent (50%) of the voting stock of the Company; (ii) a merger or consolidation in which
the Company is a party; or (iii) the sale, exchange or transfer of all or substantially all of the assets of the Company. 
 8.2
Severance. On the consummation of any Change in Control (i) any remaining unvested portion of your stock options will be accelerated such that fifty percent (50%) of your outstanding and then-unvested options become fully vested and
exercisable as of the date of the Change in Control (the “Acceleration”) and (ii) 100% of the shares subject to the Incentive Award shall accelerate and be fully exercisable immediately prior to the consummation of any Change of
Control. If on or within twelve (12) months following a Change in Control, the Company or a successor corporation terminates your employment without Cause and other as a result of your death or disability, or you resign for Good Reason (a
“Change in Control Termination”), and provided that such termination constitutes a Separation from Service, then subject to your obligations below, and in lieu of any severance benefits set forth in Section 7.3 herein, you will be
entitled to receive (collectively, the “Change in Control Severance Benefits”): 
 (a) Subject to payroll deductions and
required withholdings and net of any amounts earned by you pursuant to any employment or consulting arrangements obtained by you following such termination (other than the activities described in the last sentence of Section 3.1), continuation
for twelve (12) months of the greater of: (i) your base salary in effect as of such termination date; or (ii) your base salary as set forth in Section 2.1. In addition, you will be eligible to receive 100% of your potential
annual discretionary bonus amount set forth in Section 2.2, determined as if all performance targets established by the Board have been satisfied. 

  
 6. 

 (b) You will receive acceleration of vesting of all of your then-outstanding and
then-unvested stock option grants as of the date of termination such that the remaining fifty percent (50%) of your unvested options following the Acceleration become fully vested and exercisable. 

(c) If you timely elect and remain eligible for continued coverage of your group health insurance under COBRA, the Company will pay
your premiums for COBRA coverage for up to twelve (12) months following your Separation from Service, provided that such payments shall cease if you obtain full-time employment, or cease to be eligible for COBRA, within such period. You agree
to notify the Company promptly if you obtain full-time employment while the Company is paying your COBRA premiums under this letter agreement. On the 60th day following your Separation from
Service, the Company will make the first payment under this clause equal to the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such 60th day, with the balance of the payments paid thereafter on the schedule described above. If you become eligible for coverage under another employer’s group health plan or otherwise cease to be
eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause will cease. 

(d) As a precondition of receiving the Change in Control Severance Benefits, you must first sign and make effective on or after the
termination date a full, general release of claims against the Company in a form acceptable to the Company containing the language set forth in the Release Agreement attached as Exhibit B. 

8.3 Parachute Payments. 

(a) If any payment or distribution in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to you or
for your benefit, whether under this letter agreement or otherwise (a “Payment”), would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”) (together with any
interest or penalties imposed with respect to such excise tax, the “Excise Tax”), then you will be entitled to receive from the Company an additional payment (the “Gross-Up Payment”) in an amount equal to (i) all Excise
Taxes (including any interest or penalties imposed with respect to such taxes) on the Payment (the “First Reimbursement Payment”), (ii) all federal, state and local income taxes and employment taxes on the First Reimbursement Payment,
and (iii) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the First Reimbursement Payment. 

(b) All determinations required to be made under this Section 8.3 including whether and when a Gross-Up Payment is required and
the amount of such Gross-Up Payment and the assumptions to be utilized in arriving at such determination, shall be made by the nationally recognized certified public tax accounting firm used by the Company or, if such firm declines to serve, such
other nationally recognized certified public tax accounting firm as you may designate (the “Accounting Firm”). The Accounting Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable,
good-faith 

  
 7. 

 
interpretations concerning the application of Sections 280G and 4999 of the Code. The Accounting Firm shall provide its calculations, together with detailed supporting documentation, to the
Company and you within thirty (30) calendar days after the date on which your right to a Payment is triggered (if requested at that time by the Company or you) and/or at such other times as requested by the Company or you. If the Accounting
Firm determines that no Excise Tax is payable with respect to a Payment, it shall furnish the Company and you with an opinion reasonably acceptable to you that no Excise Tax will be imposed with respect to such Payment. If the Accounting Firm
determines that an Excise Tax is payable with respect to a Payment, it shall furnish to the Company and you an opinion reasonably acceptable to you of the amount of Excise Tax payable with respect to the Payments and the amount of Gross-Up Payment
due to you. The Company will pay the Gross-Up Payment to you within thirty (30) days of the date the Company receives the Accounting Firm’s opinion, but in no event later than the end of your tax year following your tax year in which you
pay the Excise Tax. The Company shall bear all reasonable expenses with respect to the determinations by the Accounting Firm required to be made hereunder. Any determination by the Accounting Firm shall be binding upon the Company and you. 

9. General Provisions. 

9.1 Dispute Resolution. To aid in the rapid and economical resolution of any disputes which may arise under this Agreement, the parties
agree that any and all claims, disputes or controversies of any nature whatsoever arising from or regarding the interpretation, performance, negotiation, execution, enforcement or breach of this Agreement, or your relationship with the Company,
including statutory claims, shall be resolved by confidential, final and binding arbitration conducted before a single arbitrator with Judicial Arbitration and Mediation Services, Inc. (“JAMS”) in San Francisco, California, in accordance
with JAMS’ then-applicable employment arbitration rules (which may be reviewed at www.jamsadr.com/rules-employment-arbitration/). The parties acknowledge that by agreeing to this arbitration procedure, they waive the right to resolve any
such dispute through a trial by jury, judge or administrative proceeding. The parties will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall: (i) have the authority to compel adequate
discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (ii) issue a written statement signed by the arbitrator regarding the disposition of each claim
and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The Company shall bear all JAMS’ arbitration fees and administrative costs in
excess of the amount of administrative fees (e.g., filing fees) that you would otherwise be required to pay if the dispute were decided in a court of law. Nothing in this Agreement shall prevent any party from obtaining injunctive or other
provisional relief in court to prevent irreparable harm pending the conclusion of any arbitration proceeding. 
 9.2 Severability.
Whenever possible, each provision of this letter agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this letter agreement is held to be invalid, illegal or unenforceable in any
respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but such invalid, illegal or unenforceable provision will be reformed,
construed and enforced in such jurisdiction so as to render it valid, legal, and enforceable consistent with the intent of the parties insofar as possible. 

  
 8. 

 9.3 Notices. Any notices provided hereunder must be in writing and shall be deemed
effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight courier, to the Company at its primary office location and to you at your address as listed on the Company payroll. 

9.4 Waiver. If either party should waive any breach of any provisions of this letter agreement, you or the Company shall not thereby be
deemed to have waived any preceding or succeeding breach of the same or any other provision of this letter agreement. 
 9.5 Entire
Agreement. This letter agreement, together with its exhibits, constitutes the entire and exclusive agreement between you and the Company, and it supersedes any prior agreement, promise, representation, or statement, written or otherwise, between
you and the Company with regard to this subject matter. It is entered into without reliance on any promise, representation, statement or agreement other than those expressly contained or incorporated herein, and it cannot be modified or amended
except in a writing signed by you and a duly authorized officer of the Company. 
 9.6 Counterparts. This letter agreement may be
executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same letter agreement. 

9.7 Headings. The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof
nor to affect the meaning thereof. 
 9.8 Successors and Assigns. This letter agreement is intended to bind and inure to the benefit
of and be enforceable by you, the Company and your and its respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties hereunder and you may not assign any of your rights hereunder without
the written consent of the Company. 
 9.9 Governing Law. All questions concerning the construction, validity and interpretation of
this letter agreement will be governed by the law of the State of California as applied to contracts made and to be performed entirely within California. 

9.10 Attorneys’ Fees. If either party hereto brings any action to enforce your or its rights hereunder, the prevailing party in
such action shall be entitled to be paid by the other party such prevailing party’s reasonable attorneys’ fees and costs incurred in such action. 

Enclosed is your Employee Agreement on Confidential Information and Inventions, which you should read carefully. 

To indicate your acceptance of the Company’s offer, please sign this letter agreement in the space provided below and return it to me. 

  
 9. 

			
	 Sincerely,
  

CYMABAY THERAPEUTICS

		
	By:	 	 /s/ Harold Van Wart

		 	 Harold Van Wart

		 	 Chief Executive Officer

  

	
	Accepted and agreed:
	
	/s/ Patrick O’Mara
	Patrick O’Mara

 EXHIBIT A - Employee Agreement on Confidential Information and Inventions 

EXHIBIT B - Release Agreement 

  
 10. 

 EXHIBIT A 

CymaBay Therapeutics, Inc. 

7999 Gateway Blvd., Suite 130 

Newark, CA 94560-1144 
 Phone 510
293-8800        Fax 510 293-9090 
 February 23, 2016 

EMPLOYEE AGREEMENT ON CONFIDENTIAL 

INFORMATION AND INVENTIONS 
 THIS AGREEMENT
is between CymaBay Therapeutics, Inc. a Delaware Corporation (“the Company”), and Patrick O’Mara, (the “Employee”). 

PURPOSE OF AGREEMENT 
 I want to
be employed by the Company, and the Company wants to employ me, provided that, in so doing, it can protect its trade secrets and inventions, ideas, information, business, and good will. 

In consideration of this purpose, and the mutual promises in this Agreement, I agree with the Company as follows: 

1. Term 
 (A) My
employment with the Company is an at-will relationship that may be terminated by either the Company or me with or without cause for any reason whatsoever at any time upon notice to the other party. 

(b) If my employment is terminated for any reason, I will be entitled only to the compensation earned by me as of the date of termination.

 2. Confidential Information. I will hold in confidence and use only for the benefit of the Company during the term of my
employment and for five years after the termination of my employment all Confidential Information of the Company, its Affiliates, and all Confidential Information of companies or persons other than the Company given to the Company under an agreement
prohibiting its disclosure. “Confidential Information” refers to valuable technical or business information that is not known by the public. By way of example, Confidential Information may include information relating to: inventions or
products, including unannounced products; research and development activities; requirements and specifications of specific customers and potential customers; nonpublic financial information; and quotations or proposals given to customers. 

These restrictions on disclosure do not apply if the information is or becomes publicly known through no wrongful act on my part or the
information is explicitly approved for release under such circumstances by an officer of the Company. 

  
 11. 

 3. Disclosure and Assignment of Inventions. I hereby assign to the Company my entire
right, title and interest in all inventions. “Inventions” refer to (a) all technical or business innovations, whether or not patentable or copyrightable, made by me during the term of my employment; and (b) all technical or
business innovations, whether or not patentable, based upon the Company’s Confidential Information and made by me after leaving the Company’s employ. I will keep adequate written records of all inventions made by me, such as notebooks,
sketches, program listings and the like, which are the property of the Company. Notwithstanding the foregoing, I am not required to assign to the Company, although I must disclose, any inventions: (a) for which no equipment, supplies,
facilities or Confidential Information of the Company were used and which was developed entirely on my own time; (b) which at the time of conception or reduction to practice did not relate directly to the business of the Company or the
Company’s actual or demonstrably anticipated research or development and (c) which did not result from any work I performed for the Company. The disclosure of such inventions must be made so that the parties can make a determination
whether such inventions do in fact qualify for exclusion from assignment to the Company. The Company will keep confidential any such information I disclose. I will take all steps necessary to assist the Company in securing any patents, copyrights or
other protection for inventions which I am required to assign to the Company as provided above. If I am unable or unwilling, whether during my employment or after termination, to sign any papers needed to apply for or pursue any patent or copyright
registrations for inventions, I agree that the Company is my attorney-in-fact for that purpose and can sign such papers as my agent and take any other actions necessary to pursue these registrations. 

4. List of Inventions I Own. I have attached as Exhibit A a list of inventions I own, which is a complete list of all technical or
business innovations I own either alone or jointly with others on the date of this Agreement. I agree that I will not incorporate any of these prior inventions into products being developed for the Company without the prior knowledge and written
consent of the Company. Should the Company wish to use any of my inventions in its business, the Company will negotiate with me for a purchase of or license to use such invention on mutually agreeable terms. If no such list is attached, or if no
such inventions are listed thereon, I represent that I do not own any inventions at the time of signing this Agreement. 
 5. Tangible
Materials. All tangible materials that incorporate Confidential Information are the Company’s property, and I will give all of these materials and any other documents and materials which are the property of the Company, including but not
limited all notes of any research or other work which I have performed for the Company and all biological materials created, used or held by me in the course of my work for the Company, back to the Company at the termination of my employment or
earlier upon the Company’s request. 
 6. Solicitation of Employees. I understand that information about the Company’s
employees, such as their skills, performance ratings, and salary histories, constitutes Confidential Information owned by the Company. I agree that, for a period of twelve (12) months after termination of my employment for any reason, I will
not, either directly or indirectly, solicit, induce, recruit or encourage any of the Company’s employees to leave their employment, or take away such employees, or attempt to do any of these things, whether on my own behalf or on behalf of any
other person, since to do so would necessarily involve using Confidential Information. 

  
 12. 

 8. Termination. In the event of termination of my employment for any reason, I agree that,
as requested by the Company, I will sign and deliver a “Termination Certification” in the form attached to this Agreement as Exhibit B. I also agree that the Company may give notice to my new employer of my duties under this Agreement.

 9. Duty of Loyalty. During my employment with the Company, I will not engage in any business activity (either for my own profit or
for anyone else) that competes with the Company’s business. 
 10. Duties to Third Parties. I represent that, to the best of my
knowledge, compliance with the terms of this Agreement will not violate any duty that I may have to anyone other than the Company (such as a former employer) to keep such person’s proprietary information in confidence or to refrain from using
that person’s patents or copyrights. If at any time during my employment with the Company, I am asked by the Company to perform work which I believe may cause me to violate a duty I have to someone other than the Company, I will immediately
inform an officer of the Company so that an assessment of the situation may be made. I also agree that I will not, during my employment with the Company, bring onto the Company’s premises, use or disclose to the Company any proprietary
information or trade secrets of any former employer or any other person without that person’s consent. 
 11. Miscellaneous.
This is the only agreement between the Company and myself about confidential information and the ownership of inventions, and may not be modified, amended or terminated, in whole or in part, except in a writing signed by me and by an officer of the
Company. Any later change in my title, compensation or duties will not affect this Agreement. This Agreement will survive termination of my employment for any reason, and will continue for the benefit of and will be binding upon the successors,
assigns, heirs and legal representatives of the Company and myself. Any waiver by the Company of a breach of any of the obligations of this Agreement by me will not operate or be construed as a waiver of any other or subsequent breach by me. In the
event any provision of this Agreement is held to be invalid, void or unenforceable, the remaining provisions will nevertheless continue in full force and effect without being impaired or invalidated in any way. The prevailing party in any legal
action brought by one party against the other and arising out of this Agreement shall be entitled, in addition 

  
 13. 

 
to any other rights and remedies it may have, to reimburse for its expenses, including court costs and reasonable attorney’s fees. This Agreement will be governed by the laws of the State of
California governing contracts between residents to be performed in the State of California. 
  

									
	CymaBay Therapeutics, Inc.	 		 	Employee
					
	By:	 	 /s/ Harold Van Wart
	 		 	By:	 	/s/ Patrick O’Mara
		 	 Harold Van Wart

Chief Executive Officer
	 		 	Signature
			
	   
	 	  
	 	   

	Date	 		 	Patrick O’Mara
				
	  
	 		 	  
	 	March 22, 2016
		 		 		 	Date

  
 14. 

 EXHIBIT A 

List of Inventions I Own (see para. 4.) 

  
 15. 

 EXHIBIT B 

Termination Certificate 

This is to certify that I do not have in my possession, nor have I failed to return, any devices, records, data, notes, reports, proposals,
lists, equipment, computer programs or listings, other documents or property or any reproductions of any of these materials belonging to CymaBay Therapeutics, Inc., a Delaware corporation, its subsidiaries, successors or assigns (collectively, the
“Company”). 
 I further certify that I have complied with all the terms of the Company’s Employee Confidential Information
and Inventions Agreement signed by me, including the reporting of any inventions and original works of authorship (as defined in that agreement) conceived or made buy me (solely or jointly with others) covered by that agreement. 

I further agree that, in compliance with the Employee Confidential Information and Inventions Agreement, I will preserve as confidential all
trade secrets, confidential knowledge, data or other proprietary information relating to inventions or products, including but not limited to unannounced products, research and development activities, requirements and specifications of specific
customers and potential customers, nonpublic financial information, and quotations or proposals given to customers, including any information disclosed to the Company in confidence by any third party. 

I further agree that for twelve (12) months from this date, I will not solicit, induce, recruit or encourage any of the Company’s
employees to leave their employment. 
  

	
	
	   

	Signature
	
	   

	Patrick O’Mara
	
	   

	Date

  
 16. 

 EXHIBIT B 

RELEASE AGREEMENT 

(To be signed on or after the Separation Date) 

I understand that my employment with CymaBay Therapeutics (the “Company”) terminated effective
                    ,          (the “Separation Date”). The Company has agreed that
if I choose to sign this Release Agreement (“Release”), the Company will provide certain severance benefits (minus the required withholdings and deductions) pursuant to the terms of the employment agreement dated
                     (as amended, the “Letter Agreement”). I understand that I am not entitled to such severance benefits unless I
sign this Release, and it becomes fully effective. 
 I understand that this Release, together with the Letter Agreement, constitutes the
complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated therein. 

I hereby confirm my obligations under my Employee Agreement on Confidential Information and Inventions with the Company. 

I hereby represent that I have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and
protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which I have not already filed a claim. 

In exchange for the consideration provided to me by this Release that I am not otherwise entitled to receive, I hereby generally and
completely release Company and its current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any and all claims,
liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release. This general release includes, but is not limited to: (a) all
claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay,
expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and
fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for discrimination,
harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as
amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended). 

  
 17. 

 Nothing in this Release shall prevent me from filing, cooperating with, or participating in any
proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that I hereby acknowledge and agree that I shall not recover any monetary benefits in
connection with any such proceeding. 
 I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under
the ADEA (“ADEA Waiver”). I also acknowledge that the consideration given for the ADEA Waiver is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this
writing, as required by the ADEA, that: (a) my ADEA Waiver does not apply to any rights or claims that arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release; (c) I have
twenty-one (21) days to consider this Release (although I may choose to voluntarily sign it sooner); (d) I have seven (7) days following the date I sign this Release to revoke the ADEA Waiver; and (e) the ADEA Waiver will not be
effective until the date upon which the revocation period has expired unexercised, which will be the eighth day after I sign this Release. 

I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general
release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the
debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims hereunder. 

I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than twenty-one
(21) days following the date it is provided to me. 
 I accept and agree to the terms and conditions stated above: 

 

					
			
	   
	 		 	   

	Date	 		 	Patrick O’Mara

  
 18.Exhibit 10.1

 

RESTRICTED STOCK UNIT AWARD AGREEMENT

 

Long-Term Incentive Compensation Award

_________________
Performance Period

 

This Restricted Stock Unit Award Agreement
(the “Agreement”) made under the Foot Locker 2007 Stock Incentive Plan (the “Plan”) as of the ________
day of ________ by and between Foot Locker, Inc., a New York corporation with its principal office located at 112 West 34th Street,
New York, New York 10120 (the “Company”) and ______________ (“Executive”).

 

1. General.
As a participant in the Company’s long-term incentive compensation program for the __________ Performance Period which
covers the fiscal years beginning __________ and __________ (the “Performance Period”), you were granted a
long-term incentive award that will be payable following the end of the Performance Period, provided the performance goals
set by the Compensation and Management Resources Committee (the “Compensation Committee”) of the Board of
Directors of the Company on ________ for the Performance Period are achieved. The award is payable as follows: 25 percent of
the award is payable in cash under the Long-Term Incentive Compensation Plan (the “LTIP”), and 75 percent of the
award is payable in restricted stock units (“RSUs”) under the Plan as provided herein. The RSUs are intended to
constitute “Other Stock-Based Awards” under the Plan. Each RSU represents the right to receive one share of the
Company’s Common Stock, par value $.01 per share (“Common Stock”), upon the satisfaction of the terms and
conditions set forth in this Agreement and the Plan.

 

This Agreement sets forth the terms and
conditions with regard to the portion of your long-term award that is payable in RSUs. You have been granted __________ RSUs,
subject to the conditions set forth herein. Unless otherwise indicated, any capitalized term used but not defined herein shall
have the meaning ascribed to such term in the Plan.

 

2. Earning of
RSUs. Subject to the terms and conditions of the Plan and this Agreement, you shall be entitled to receive, for each RSU
earned in accordance with this Section 2 and Appendix A hereto, one share of Common Stock. You shall earn the number of RSUs
set forth above for achievement at the maximum performance goal as specified in Appendix A attached hereto, subject
to adjustment for achievement below the maximum performance goal in accordance with the provisions of Appendix A attached
hereto. If the threshold performance level set forth in Appendix A is not achieved, none of the RSUs granted to you shall be
earned. The Compensation Committee shall certify the level of achievement of the performance goals during the Company’s
first fiscal quarter in _________ and at such time shall determine the number of RSUs you are eligible to receive, subject to
the provisions of Section 3 below.

 

3. Vesting and
Delivery.

 

(a) The RSUs you
are eligible to receive as described in Section 2 shall be subject to a one-year vesting period following the end of the
Performance Period and shall become vested on _________ (the “Vesting Date”). Subject to the terms of
this Agreement and

    	 

    	

    

 the Plan, shares of Common Stock equal to the number of RSUs you earn shall be delivered to you as
described below if you have been continuously employed by the Company or its subsidiaries within the meaning of Section 424
of the Code (the “Control Group”) from the Date of Grant until the Vesting Date.

 

(b) Other than as
specifically provided herein, there shall be no proportionate or partial vesting in the periods prior to the Vesting Date,
and all vesting shall occur only on the Vesting Date, subject to your continued employment with the Control Group as
described in Section 3(a).

 

(c) If the Company
terminates your employment without Cause or you terminate your employment for Good Reason upon or following a Change in
Control as defined in Appendix B hereto and such Change in Control occurs following the end of the Performance Period and
the certification by the Compensation Committee of the achievement of the performance goal, all unvested RSUs shall become
immediately vested and shall be paid in accordance with Section 3(f).

 

(d) If the Company
terminates your employment without Cause or you terminate your employment for Good Reason upon, or within twenty-four (24)
months following, a Change in Control as defined in Appendix B hereto and your Termination occurs prior to the end of
the Performance Period, or coincident with or following the end of the Performance Period and prior to the certification by
the Compensation Committee of the achievement of the performance goal, you shall be entitled to receive a pro rata portion of
the RSUs that you would have been entitled to receive based on the actual performance level achieved for any completed year
in the Performance Period and the achievement of a target performance level for the remainder of the Performance Period, as
set forth in Appendix A, such RSUs shall become immediately vested upon your Termination and shall be paid in accordance with
Section 3(f). The pro rated portion shall be determined by multiplying the number of RSUs you would have been entitled to
receive if you had not incurred such Termination by a fraction, the numerator of which is the number of days from
_____________ to the earlier of your date of Termination or the last day of the Performance Period and the denominator of
which is the total number of days in the Performance Period.

 

(e) In the event
of your Termination by reason of death, Disability (within the meaning of Code Section 409A(a)(2)(C)(i) or (ii)) or
Retirement prior to the Vesting Date, on the Vesting Date you (or in the event of your death, your estate) shall receive
a pro rata portion of the RSUs that you would have received if you had been employed by the Company on the Vesting Date,
based on the actual level of achievement of the performance goals set forth in Appendix A. The pro rated portion shall be
determined by multiplying the number of RSUs you would have been entitled to receive if you had not incurred such Termination
by a fraction, the numerator of which is the number of days from ________________ to the date of your Termination and the
denominator of which is the total number of days in the Performance Period, and shall vest on the Vesting Date and shall be
paid in accordance with Section 3(f).

 

(f) Subject to
Sections 8 and 12(k), the Company shall issue and deliver to you shares of the Company’s Common Stock equal to the
number of vested RSUs you earn 

    	2

    	

    

within 30 days following the earlier of a Termination described in Section 3(d) or the
Vesting Date.

 

4. Forfeiture.

 

(a) Any RSUs that
are not earned in accordance with Section 2 or vested in accordance with Section 3 of this Agreement shall be
forfeited without compensation following the Compensation Committee’s certification of the goals for the Performance
Period.

 

(b) Except as
expressly set forth in Section 3(e), in the event of your Termination prior to the Vesting Date or your breach of
the Non-Competition Provision in Section 10, all unvested RSUs shall be forfeited to the Company, without compensation.

 

5. Adjustments.
RSUs shall be subject to the adjustment provisions included in Section 5(e) of the Plan. In the event of any such adjustment,
the adjusted award shall be subject to the same vesting schedule as the RSUs, as set forth in Section 3.

 

6. Withholding.
You agree that:

 

(a) The Company
shall have the right to withhold the number of shares of stock from the award sufficient to satisfy any federal,
state, international, or local taxes of any kind required by law to be withheld with respect to the vesting of any RSUs which
shall have become so vested, as calculated by the Company; and

 

(b) The Company
shall, to the extent permitted by law, have the right to deduct from any payment of any kind otherwise due to you any
federal, state, international or local taxes of any kind required by law to be withheld with respect to any RSUs which
shall have become so vested.

 

7. Special
Incentive Compensation. You agree that the award of the RSUs is special incentive compensation and that the RSUs will not
be taken into account as “salary” or “compensation” or “bonus” in determining the amount
of any payment under any pension, retirement or profit-sharing plan of the Company or any life insurance, disability or other
benefit plan of the Company, except as specifically provided in any such plan.

 

8. Delivery
Delay. Notwithstanding anything herein, the delivery of any shares of Common Stock for vested RSUs may be postponed by
the Company for such period as may be required for it to comply with any applicable federal or state securities law, or
any national securities exchange listing requirements and the Company is not obligated to issue or deliver any securities if,
in the opinion of counsel for the Company, the issuance of such shares shall constitute a violation by you or the Company of
any provisions of any law or of any regulations of any governmental authority or any national securities exchange.

 

9. Restriction
on Transfer of RSUs. You shall not sell, negotiate, transfer, pledge, hypothecate, assign or otherwise dispose of the
RSUs. Any attempted sale, negotiation, transfer, pledge, hypothecation, assignment or other disposition of the RSUs
or unvested shares in violation of the Plan or this Agreement shall be null and void.

    	3

    	

    

10. Non-Competition.

 

(a) Competition.
By accepting this award of RSUs, as provided below, you agree that during the “Non-Competition Period” you will
not engage in “Competition” with the Control Group. As used herein, “Competition” means:

 

(i) participating, directly or
indirectly, as an individual proprietor, stockholder, officer, employee, director, joint venturer, investor, lender, or in
any capacity whatsoever within the United States of America or in any other country where any of your former employing
members of the Control Group does business, in (A) a business in competition with the retail, catalog, or on-line sale of
athletic footwear, athletic apparel and sporting goods conducted by the Control Group (the “Athletic Business”),
or (B) a business that in the prior fiscal year supplied product to the Control Group for the Athletic Business having a
value of $20 million or more at cost to the Control Group; provided, however, that such participation shall not include
(X) the mere ownership of not more than 1 percent of the total outstanding stock of a publicly held company; (Y) the
performance of services for any enterprise to the extent such services are not performed, directly or indirectly, for a
business in competition with the Athletic Business or for a business which supplies product to the Control Group for the
Athletic Business; or (Z) any activity engaged in with the prior written approval of the Chief Executive Officer of the
Company; or

 

(ii) intentionally recruiting,
soliciting or inducing, any employee or employees of the Control Group to terminate their employment with, or otherwise cease
their relationship with the former employing members of the Control Group where such employee or employees do in fact so
terminate their employment.

 

(b) “Non-Competition
Period”. As used herein, “Non-Competition Period” means: the period commencing ________________ and
ending on the Vesting Date, or any part thereof, during which you are employed by the Control Group and (ii) if your
employment with the Control Group terminates for any reason during such period, the two-year period commencing on the date
your employment with the Control Group terminates. Notwithstanding the foregoing, the Non-Competition Period shall not
extend beyond the date your employment with the Control Group terminates if such termination of employment occurs following a
“Change in Control” as defined in Attachment B hereto.

 

(c) Breach of
Non-Competition Provision. You agree that your breach of the provisions included herein under Section 10 under the
heading “Non-Competition” (the “Non-Competition Provision”) would result in irreparable injury
and damage to the Company for which the Company would have no adequate remedy at law. You agree, therefore, that in the event
of a breach or a threatened breach of the Non-Competition Provision, the Company shall be entitled to (i) an immediate
injunction and restraining order to prevent such breach, threatened breach, or continued breach, including by any and all
persons acting for or with you, without having to prove damages, and (ii) any other remedies to which the Company may be
entitled at law or in equity. The terms of this paragraph shall not prevent the Company from pursuing any other available
remedies for any breach or threatened breach of the Non-Competition Provision, including, but not limited to, recovery of
damages. In addition, in the event of your breach of the Non-Competition Provision, the RSUs covered by this Agreement that
are then unvested shall be 

    	4

    	

    

immediately forfeited. You and the Company further agree that the Non-Competition Provision is
reasonable and that the Company would not have granted the award of RSUs provided for in this Agreement but for the inclusion
of the Non-Competition Provision herein. If any provision of the Non-Competition Provision is found by any court of competent
jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or
in too broad a geographic area, it shall be interpreted to extend over the maximum period of time, range of activities, or
geographic area as to which it may be enforceable. The validity, construction, and performance of the Non-Competition
Provision shall be governed by the laws of the State of New York without regard to its conflicts of laws principles. For
purposes of the Non-Competition Provision, you and the Company consent to the jurisdiction of state and federal courts in New
York County, New York.

 

11. Not an
Employment Agreement.

 

The award of RSUs hereunder does not constitute
an agreement by the Company to continue to employ you during the entire, or any portion of the, term of this Agreement, including
but not limited to any period during which the RSUs are outstanding.

 

12. Miscellaneous.

 

(a) In no
event shall any dividend equivalents accrue or be paid on any RSUs.

 

(b) This Agreement
shall inure to the benefit of and be binding upon all parties hereto and their respective heirs, legal
representatives, successors and assigns.

 

(c) This Agreement
shall be subject to any compensation recoupment policy that the Company may adopt.

 

(d) This Agreement
constitutes the entire agreement between the parties and cannot be changed or terminated orally. No modification or waiver of
any of the provisions hereof shall be effective unless in writing and signed by the party against whom it is sought to be
enforced.

 

(e) This Agreement
may be executed in one or more counterparts, all of which taken together shall constitute one contract.

 

(f) The failure of
any party hereto at any time to require performance by another party of any provision of this Agreement shall not affect the
right of such party to require performance of that provision, and any waiver by any party of any breach of any provision of
this Agreement shall not be construed as a waiver of any continuing or succeeding breach of such provision, a waiver of
the provision itself, or a waiver of any right under this Agreement.

 

(g) This Agreement
is subject, in all respects, to the provisions of the Plan, and to the extent any provision of this Agreement contravenes or
is inconsistent with any provision of the Plan, the provisions of the Plan shall govern.

    	5

    	

    

(h) The headings
of the sections of this Agreement have been inserted for convenience of reference only and shall in no way restrict or modify
any of the terms or provisions hereof.

 

(i) All notices,
consents, requests, approvals, instructions and other communications provided for herein shall be in writing and validly
given or made when delivered, or on the second succeeding business day after being mailed by registered or certified
mail, whichever is earlier, to the persons entitled or required to receive the same, at, in the case of the Company, the
address set forth at the heading of this Agreement and, in the case of you, your principal residence address as shown in the
records of the Company, or to such other address as either party may designate by like notice. Notices to the Company shall
be addressed to the General Counsel.

 

(j) This Agreement
shall be governed and construed and the legal relationships of the parties determined in accordance with the laws of the
State of New York without regard to its conflicts of laws principles.

 

(k) Although the
Company does not guarantee the tax treatment of the RSUs, this Agreement is intended to comply with, or be exempt from, the
applicable requirements of Code Section 409A and shall be limited, construed and interpreted in accordance with such intent.
Accordingly, in the event that you are a “specified employee” within the meaning of Code Section 409A as of the
date of your separation from service (as determined pursuant to Code Section 409A and any procedure set by the Company),
any award of RSUs payable as a result of such separation from service shall be settled no earlier than the day following the
six- month anniversary of your separation from service, or, if earlier, your death.

 

(l) To indicate
your acceptance of the terms of this Agreement, you must sign and deliver or mail not later than 30 days following the date
hereof a copy of this Agreement to the Company at the address provided in the heading of this Agreement.

 

IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed as of the day and year first above written.

 

	 	FOOT LOCKER, INC.	 
	 	 	 	 
	 	By:	 	 
	 	 	 	 
	 	 	 	 
	 	 	Executive	 

    	6

    	

    

APPENDIX A

 

	Number
    of

    RSUs at

    Threshold

    Payout	 	Number
    of

    RSUs at

    Target Payout	 	Number
    of

    RSUs at

    Maximum

    Payout
	 	 	 	 	 

 

[Performance Goals for
_________ Performance Period]

    	7

    	

    

APPENDIX B

 

Change in Control

 

A Change in Control shall mean any of the following:

 

(A) the merger or consolidation of
the Company with, or the sale or disposition of all or substantially all of the assets of the Company to, any person or
entity or group of associated persons or entities (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities
Exchange Act of 1934 (the “Exchange Act”)) (a “Person”) other than (a) a merger or consolidation
which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving or parent entity) fifty
percent (50%) or more of the combined voting power of the voting securities of the Company or such surviving or parent entity
outstanding immediately after such merger or consolidation; or (b) a merger or capitalization effected to implement a
recapitalization of the Company (or similar transaction) in which no Person is or becomes the beneficial owner, directly or
indirectly (as determined under Rule 13d-3 promulgated under the Exchange Act), of securities representing more than the
amounts set forth in (B) below;

 

(B) the acquisition of direct or
indirect beneficial ownership (as determined under Rule 13d-3 promulgated under the Exchange Act), in the aggregate, of
securities of the Company representing thirty-five percent (35%) or more of the total combined voting power of the
Company’s then issued and outstanding voting securities by any Person (other than the Company or any of its
subsidiaries, any trustee or other fiduciary holding securities under any employee benefit plan of the Company, or any
company owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their
ownership of Common Stock of the Company) acting in concert; or

 

(C) during any period of not more than
twelve (12) months, individuals who at the beginning of such period constitute the Board, and any new director whose election
by the Board or nomination for election by the Company’s shareholders was approved by a vote of at least two-thirds (2⁄3)
of the directors then still in office who either were directors at the beginning of the period or whose election or nomination
for election was previously so approved, cease for any reason to constitute at least a majority thereof.

 

This definition of Change in Control is intended to be construed
as defined in the Plan and shall be interpreted in a manner consistent with Treasury Regulation §
1.409A-3(i)(5).

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]